Effect of tocilizumab and thymalin on systemic inflammation in patients with COVID-19
- Authors: Kuznik B.I1,2, Khavinson V.K.3,4, Lukyanov S.A1,5, Shapovalov K.G1,5, Smolyakov Y.N1,2, Tereshkov P.P1, Shapovalov Y.K1,5, Konnov V.A1,5, Zaitsev D.N1, Magen E.6
-
Affiliations:
- Chita State Medical Academy
- Innovation Clinic Academy of Health
- Saint Petersburg Institute of Bioregulation and Gerontology
- I.P. Pavlov Institute of Physiology Russian Academy of Sciences
- City Clinical Hospital One
- David Ben-Gurion University
- Issue: Vol 31, No 11 (2020)
- Pages: 87-96
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/114333
- DOI: https://doi.org/10.29296/25877305-2020-11-17
- ID: 114333
Cite item
Abstract
Full Text
About the authors
B. I Kuznik
Chita State Medical Academy; Innovation Clinic Academy of Health
Email: bi_kuznik@mail.ru
Professor, MD Chita
V. Kh Khavinson
Saint Petersburg Institute of Bioregulation and Gerontology; I.P. Pavlov Institute of Physiology Russian Academy of Sciences
Email: bi_kuznik@mail.ru
Professor, Corresponding Member of the Russian Academy of Sciences, MD Saint Petersburg
S. A Lukyanov
Chita State Medical Academy; City Clinical Hospital One
Email: bi_kuznik@mail.ru
Candidate of Medical Sciences Chita
K. G Shapovalov
Chita State Medical Academy; City Clinical Hospital One
Email: bi_kuznik@mail.ru
Professor, MD Chita
Yu. N Smolyakov
Chita State Medical Academy; Innovation Clinic Academy of Health
Email: bi_kuznik@mail.ru
Candidate of Medical Sciences Chita
P. P Tereshkov
Chita State Medical Academy
Email: bi_kuznik@mail.ru
Candidate of Medical Sciences
Yu. K Shapovalov
Chita State Medical Academy; City Clinical Hospital One
Email: bi_kuznik@mail.ru
Chita
V. A Konnov
Chita State Medical Academy; City Clinical Hospital One
Email: bi_kuznik@mail.ru
Candidate of Medical Sciences Chita
D. N Zaitsev
Chita State Medical Academy
Email: bi_kuznik@mail.ru
Associate Professor, MD
E. Magen
David Ben-Gurion University
Email: bi_kuznik@mail.ru
Professor, MD Ashdod, Israel
References
- Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497-506. doi: 10.1016/S0140-6736(20)30183-5
- Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (14): 1406-7. doi: 10.1001/jama.2020.1585
- Goh K.J., Choong M.C., Cheong E.H. et al. Rapid Progression to Acute Respiratory Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19 Infection. Ann Acad Med Singapore. 2020; 49: 108-18.
- Izet M., Nabil N., Zildzic M. Public Health Aspects of COVID-19 Infection With Focus on Cardiovascular Disea. Mater Sociomed. 2020; 32 (1): 71-6. doi: 10.5455/msm.2020.32.71-76
- Zhavoronkov A. Geroprotective and Senoremediative Strategies to Reduce the Comorbidity, Infection Rates, Severity, and Lethality in Gerophilic and Gerolavic Infections. Aging (Albany NY). 2020; 12 (8): 6492-510. DOI: 10.18632/ aging.102988
- Fu B., Xu X., Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020; 18: 164. doi: 10.1186/s12967-020-02339-3
- Russell S.M., Alba-Patino A., Baron E. et al. Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead. ACS Sens. 2020; 5 (6): 1506-13. doi: 10.1021/acssensors.0c00979
- Tang Y., Liu J., Zhang D. et al. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. Front Immunol. 2020; 11: 1708. doi: 10.3389/fimmu.2020.01708
- Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; 71 (15): 762-8. DOI: 10.1093/ cid/ciaa248
- Zhang C., Wu Z., Li J. et al. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55 (5): 105954. doi: 10.1016/j.ijantimicag.2020.105954
- Xu Z., Shi L., Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8 (4): 420-2. doi: 10.1016/S2213-2600(20)30076-X
- Chen Y., Feng Z., Diao B. et al. The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes. medRxiv. 2020: 105924. doi: 10.1101/2020.03.27.20045427
- Li J., Guo M., Tian X. et al. Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis. bioRxiv. 2020. doi: 10.1101/2020.03.31.019216
- Dhampalwar S., Saigal S., Soin A. Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. Clin Exp Hepatol. 2020. doi: 10.1016/j.jceh.2020.07.001
- Conrozier T., Lohse A., Balblanc J.C. et al. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Clin Exp Rheumatol. 2020; 38 (4): 742-7.
- Alattar R., Ibrahim T.B.H., Shaar S.H. Tocilizumab for the treatment of severe COVID-19. J Med Virol. 2020. doi: 10.1002/jmv.25964
- Wang D., Hu B., Hu C. et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-9. doi: 10.1001/jama.2020.1585
- Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020; 18 (5): 1094-9. doi: 10.1111/jth.14817
- Tang N., Li D., Wang X. et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844-7. doi: 10.1111/jth.14768
- Toniati P., Piva S., Cattalini M. et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020; 19 (7): 102568. doi: 10.1016/j.autrev.2020.102568
- Zhao J., Cui W., Tian B. Efficacy of tocilizumab treatment in severely ill COVID-19 patients. Crit Care. 2020; 24 (1): 1-4. doi: 10.1186/s13054-020-03224
- Mullard A. Anti-IL-6Rs falter in COVID-19. Nat Rev Drug Discov. 2020; 19 (9): 577. doi: 10.1038/d41573-020-00141-w
- Хавинсон В.Х., Кузник Б.И., Стуров В.Г. и др. Применение препарата Тималин® при заболеваниях органов дыхания. Перспективы использования при COVID-19. РМЖ. 2020; 9: 24-30.
- Кузник Б.И., Хавинсон В.Х. Влияние Тималина на системы иммунитета, гемостаза и уровень цитокинов у пациентов с различными заболеваниями. Перспективы применения при COVID-19. Врач. 2020; 31 (7): 18-26. doi: 10.29296/25877305-2020-07-03.
- Хавинсон В.Х., Кузник Б.И. Осложнения у больных C0VID-19. Предполагаемые механизмы коррекции. Клиническая медицина. 2020; 4: 256-65. doi: 10.30629/0023-2149-2020-98-4-256-265
- Кузник Б.И., Лиханов И.Д., Цепелев В.Л. и др. Теоретические и клинические аспекты биорегулирующей терапии в хирургии и травматологии. Новосибирск: Наука, 2008; 312 с.
- Хавинсон В.Х., Кузник Б.И., Рыжак Г.А. Пептидные геропротекторы -эпигенетические регуляторы физиологических функций организма. СПб: Изд-во РГПУ им. И.А Герцена, 2014; 279 с.
- Кузник Б.И., Васильев В.Н., Цыбиков Н.Н. Иммуногенез, гемостаз и неспецифическая резистентность организма. М.: Медицина, 1989; 320 с.
- Кузник Б.И., Витковский Ю.А. Люлькина Е.В. Возрастные особенности системы гемостаза у людей. Успехи геронтологии. 2005; 16: 38-47.
- Лукьянов С.А., Кузник Б.И., Хавинсон В.Х. и др. Использование Тималина для коррекции отклонений иммунного статуса при COVID-19 (обоснование применения препарата и описание клинического случая). Врач. 2020; 31 (8): 74-82. doi: 10.29296/25877305-2020-08-12